Eli Lilly is in talks to acquire psychedelic drugmaker AtaiBeckley, with a deal possibly announced this week, according to Bloomberg News. AtaiBeckley shares soared 66% in aftermarket trading, while Lilly was flat. AtaiBeckley was up 31% so far this year and had a market value of $1.97 billion as of Wednesday’s close.
Psychedelic-Based Treatments
New York-based AtaiBeckley focuses on psychedelic-based treatments for mental health conditions and is developing BPL-003, an intranasal formulation of 5-MeO-DMT for treatment-resistant depression. The company’s shares received a boost this year after U.S. President Donald Trump ordered health regulators to speed up reviews of psychedelic treatments and increased federal funding for their research.
Original reporting: Appleton, WI News Feed (HLL/CB) — read the source article.